IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Journal of Experimental Medicine · 01.05.2023 · 220 (5)
DOI: 10.1084/jem.20221952 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Experimental Medicine, online erschienen am 15.03.2023. Verfasst von Irene L M Reijers und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Netherlands Cancer Institute , Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, University of Sydney, 4SC AG, Planegg-Martinsried.
Abstract (Originalsprache)
Neoadjuvant ipilimumab + nivolumab has demonstrated high pathologic response rates in stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less likely to benefit. We show that domatinostat (a class I histone deacetylase inhibitor) addition to anti-PD-1 + anti-CTLA-4 increased the IFN-γ response and reduced tumor growth in our murine melanoma model, rationalizing evaluation in patients. To stratify patients into IFN-γ high and low cohorts, we developed a baseline IFN-γ signature expression algorithm, which was prospectively tested in the DONIMI trial. Patients with stage III melanoma and high intra-tumoral IFN-γ scores were randomized to neoadjuvant nivolumab or nivolumab + domatinostat, while patients with low IFN-γ scores received nivolumab + domatinostat or ipilimumab + nivolumab + domatinostat. Domatinostat addition to neoadjuvant nivolumab ± ipilimumab did not delay surgery but induced unexpected severe skin toxicity, hampering domatinostat dose escalation. At studied dose levels, domatinostat addition did not increase treatment efficacy. The baseline IFN-γ score adequately differentiated patients who were likely to benefit from nivolumab alone versus patients who require other therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Netherlands Cancer Institute , Amsterdam, Netherlands.
- Molecular Oncology and Immunology, Netherlands Cancer Institute , Amsterdam, Netherlands.
- Melanoma Institute Australia, The University of Sydney , Sydney, Australia.
- Faculty of Medicine and Health, The University of Sydney , Sydney, Australia.
- Department of Medical Oncology, Royal North Shore and Mater Hospitals , Sydney, Australia.
- Department of Surgical Oncology, Netherlands Cancer Institute , Amsterdam, Netherlands.
ORCID-Profile: Irene L M Reijers, Disha Rao, Judith M Versluis, Alexander M Menzies, Petros Dimitriadis, Michel W Wouters, Andrew J Spillane, Willem M C Klop, Annegien Broeks, Linda J W Bosch, Marta Lopez-Yurda, Winan J van Houdt, Robert V Rawson, Lindsay G Grijpink-Ongering, Maria Gonzalez, Sten Cornelissen, Joyce Sanders, Elsemieke Plasmeijer, Yannick S Elshot, Richard A Scolyer, Bart A van de Wiel, Daniel S Peeper, Alexander C J van Akkooi, Georgina V Long, Christian U Blank
Förderung
- National Health and Medical Research Council
- University of Sydney
- 4SC AG, Planegg-Martinsried
Zitieren
APA
Reijers, I. L. M., Rao, D., Versluis, J. M., Menzies, A. M., Dimitriadis, P., Wouters, M. W., Spillane, A. J., Klop, W. M. C., Broeks, A., Bosch, L. J. W., Lopez-Yurda, M., van Houdt, W. J., Rawson, R. V., Grijpink-Ongering, L. G., Gonzalez, M., Cornelissen, S., Bouwman, J., Sanders, J., Plasmeijer, E., …, & Blank, C. U. (2023). IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma. Journal of Experimental Medicine, 220(5). https://doi.org/10.1084/jem.20221952
Vancouver
Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, et al. IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma. Journal of Experimental Medicine. 2023;220(5). doi:10.1084/jem.20221952
BibTeX
@article{Reijers2023,
author = {Reijers, Irene L M and Rao, Disha and Versluis, Judith M and Menzies, Alexander M and Dimitriadis, Petros and Wouters, Michel W and Spillane, Andrew J and Klop, Willem M C and Broeks, Annegien and Bosch, Linda J W and Lopez-Yurda, Marta and van Houdt, Winan J and Rawson, Robert V and Grijpink-Ongering, Lindsay G and Gonzalez, Maria and Cornelissen, Sten and Bouwman, Jasper and Sanders, Joyce and Plasmeijer, Elsemieke and Elshot, Yannick S and Scolyer, Richard A and van de Wiel, Bart A and Peeper, Daniel S and van Akkooi, Alexander C J and Long, Georgina V and Blank, Christian U},
title = {IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma},
journal = {Journal of Experimental Medicine},
year = {2023},
volume = {220},
number = {5},
doi = {10.1084/jem.20221952}
}
EUVIMED